Ono Pharmaceutical Co Stock Beta
| OPHLF Stock | USD 11.35 1.09 10.62% |
Ono Pharmaceutical Co fundamentals help investors to digest information that contributes to Ono Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Ono Pink Sheet. The fundamental analysis module provides a way to measure Ono Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ono Pharmaceutical pink sheet.
Ono |
Ono Pharmaceutical Co Company Beta Analysis
Ono Pharmaceutical's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Ono Pharmaceutical Beta | 0.26 |
Most of Ono Pharmaceutical's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ono Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Ono Pharmaceutical Co has a Beta of 0.2566. This is 70.16% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The beta for all United States stocks is notably lower than that of the firm.
Ono Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ono Pharmaceutical's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ono Pharmaceutical could also be used in its relative valuation, which is a method of valuing Ono Pharmaceutical by comparing valuation metrics of similar companies.Ono Pharmaceutical is currently under evaluation in beta category among its peers.
As returns on the market increase, Ono Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ono Pharmaceutical is expected to be smaller as well.
Ono Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 488.31 M | |||
| Shares Owned By Insiders | 16.04 % | |||
| Shares Owned By Institutions | 44.41 % | |||
| Price To Earning | 18.12 X | |||
| Price To Book | 2.29 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 361.36 B | |||
| Gross Profit | 267.85 B | |||
| EBITDA | 123.45 B | |||
| Net Income | 80.52 B | |||
| Cash And Equivalents | 136.18 B | |||
| Cash Per Share | 278.93 X | |||
| Total Debt | 8.65 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | 1,477 X | |||
| Cash Flow From Operations | 61.83 B | |||
| Earnings Per Share | 1.74 X | |||
| Price To Earnings To Growth | 40,587 X | |||
| Number Of Employees | 3.69 K | |||
| Beta | 0.26 | |||
| Market Capitalization | 10.62 B | |||
| Total Asset | 739.2 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 739.2 B | |||
| Last Dividend Paid | 28.0 |
About Ono Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ono Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ono Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ono Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Ono Pink Sheet
Ono Pharmaceutical financial ratios help investors to determine whether Ono Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ono with respect to the benefits of owning Ono Pharmaceutical security.